BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Saturday, April 20, 2024
Home
»
Newsletters
» BioWorld
BioWorld
Nov. 7, 2006
View Archived Issues
Adolor Suffers Setback On FDA Request For More Entereg Data
The FDA delayed approving Adolor Corp.'s Entereg (alvimopan) for postoperative ileus yet again, pending additional safety data, causing the company's shares to tumble by 44.8 percent on Monday. (BioWorld Today)
Read More
Biotech Rides Wave Of M&A; Licensing Deals Remain Hot
Read More
Ambit, Cephalon Enter Potential $250M Deal On Kinase Inhibitors
Read More
Abbott Paying $3.7B For Kos In Move To Bolster Lipids Portfolio
Read More
Celgene Raises $1B As Part Of Addition To S&P 500 Index
Read More
Clinic Roundup
Read More
Other News To Note
Read More